Development of a Liposome Formulation for D-Cycloserine Local Delivery

References

• N. G. Cascella, F. Macciardi, C. Cavallini, and E. Smeraldi. (1994). D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm 95:105–11.
   Web of Science ®Google Scholar
• G. N. Chiu, M. B. Bally, and L. D. Mayer. (2002). Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochim Biophys Acta 1560:37–50.
   PubMed Web of Science ®Google Scholar
• J. Cieslak, I. Busko, and Z. Makarowska-Plociennik. (1967). Decomposition of cycloserine during chemical treatment of culture liquid. Antibiotiki 12 (5):410–14.
   Google Scholar
• D. J. A. Crommelin, and R. D. Sindelar. (2002). Pharmaceutical biotechnology: An introduction for pharmacists and pharmaceutical scientists. London: Routledge, Taylor & Francis Group, pp 96–9.
   Google Scholar
• M. Dahlin, U. Bergman, n. B Jansso, E. Björk, and E. Brittebo. (2000). Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res. 7 (6):737–42.
   Google Scholar
• S. David. (2001). Synergic activity of D-cycloserine and beta-chloro-D-alanine against Mycobacterium tuberculosis. J Antimicrob Chemother 47:203–06.
   Google Scholar
• E. J. Duncan, S. Szilagyi, M. P. Schwartz, D. Bugarski-Kirola, A. Kunzova, S. Negi, M. Stephanides, T. R. Efferen, B. Angrist, E. Peselow, J. Corwin, S. Gonzenbach, and J. P. Rotrosen. (2004). Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res 7:239–48.
   Google Scholar
• T. N. Estep, D. B. Mountcastle, R. L. Biltonen, R. L. Biltonen, and T. E. Thompson. (1978). Thermal behaviour of synthetic sphingomyelin-cholesterol dispersion. Biochemistry 18:2112–17.
   Google Scholar
• A. E. Evins, E. Amico, Toker R. Posever, and D. C. Goff. (2002). D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 56:19–23.
   PubMed Web of Science ®Google Scholar
• J. F. Flood, J. E. Morley, and T. H. Lanthorn. (1992). Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor. Eur J Pharmacol 221:249–54.
   PubMed Web of Science ®Google Scholar
• T. J. Franklin, and G. A. Snow. (1989). Biochemistry of antimicrobial action, 4th Ed. London: Chapman and Hall.
   Google Scholar
• M. Fresta, S. Guccione, A. R. Beccari, P. M. Furneri, and G. Puglisi. (2002). Combining molecular modelling with experimental methodologies: Mechanism of membrane permeation and accumulation of ofloxacin. Bioorg Med Chem 10:3871–89.
   PubMed Web of Science ®Google Scholar
• R. Galović Rengel, K. Barisić, Z. Pavelić, T. Zanic Grubisić, I. Cepelak, and J. Filipović-Grcić. (2002). High efficiency entrapment of superoxide dismutase into mucoadhesive chitosan-coated liposomes. Eur J Pharm Sci 15:441–48.
   PubMed Web of Science ®Google Scholar
• D. C. Goff, D. C. Henderson, A. E. Evins, and E. Amico. (1999a). A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 45:512–14.
   PubMed Web of Science ®Google Scholar
• D. C. Goff, G. Tsai, D. S. Manoach, and J. T. Coyle. (1995). A dose finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213–15.
   PubMed Web of Science ®Google Scholar
• D. C. Goff, G. Tsai, D. S. Manoach, J. Flood, D. G. Darby, and J. T. Coyle. (1996). D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153:1628–30.
   PubMedGoogle Scholar
• D. Goff, G. Tsai, J. Levitt, E. Amico, D. Manoach, D. A. Schoenfeld, D. L. Hayden, R. McCarley, and J. T. Coyle. (1999b). A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21–7.
   PubMed Web of Science ®Google Scholar
• G. Gregoriadis, and A. T. Florence. (1993). Liposomes in drug delivery, clinical, diagnostic and ophthalmic potential. Drugs 45:15–28.
   PubMed Web of Science ®Google Scholar
• W. F. Hood, R. P. Compton, and J. B. Monahan. (1989). D-cycloserine: a ligand for the N-methyl-D-aspartate-coupled glycine receptor has partial agonist characteristics. Neurosc Lett 98:1167–71.
   Google Scholar
• M. K. Jain. (1988a). Properties of bilayer. In: M.K. Jain. (Ed.). Introduction to biological membranes. New York: John Wiley & Sons, Inc., pp 86–121.
   Google Scholar
• M. K. Jain. (1988b). Order and dynamics in bilayers and solute in bilayers. In: M.K. Jain. (Ed.). Introduction to biological membranes. New York: John Wiley & Sons, Inc., pp 122–46.
   Google Scholar
• V. V. Jogani, P. J. Shah, P. Mishra, A. K. Mishra, and A. R. Misra. (2007). Nose-to-brain delivery of tacrine. J Pharm Pharmacol. 59 (9):1199–205.
   Google Scholar
• S. L. Law, K. J. Huang, and H. Y. Chou. (2001). Preparation of desmopresin-containing liposomes for intranasal delivery. J. Control Release 70 (3):375–82.
   Google Scholar
• S. Mathison, R. Nagilla, and U. B. Kompella. (1998). Nasal route for direct delivery of solutes to the central nervous system: Fact or fiction?. J Drug Target 5 (6):415–41.
   Google Scholar
• L. D. Mayer, L. C. Tai, D. S. Ko, D. Masin, R. S. Ginsberg, P. R. Cullis, and M. B. Bally. (1989). Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49:5922–30.
   PubMed Web of Science ®Google Scholar
• A. Panico, R. Pignatello, V. Cardile, and G. Puglisi. (1997). Preparation of liposome formulations containing immunomodulatory peptides. Pharm Acta Helv 72:1–10.
   Google Scholar
• C. Pettenati, R. Annicchiarico, and C. Caltagirone. (2003). Clinical pharmacology of anti-Alzheimer drugs. Fundam Clin Pharmacol 17:659–72.
   Web of Science ®Google Scholar
• R. Pignatello, S. Guccione, F. Castelli, M. G. Sarpietro, L. Giurato, M. Lombardo, G. Puglisi, and I. Toth. (2006). Enhancement of drug affinity for cell membranes by conjugation with lipoamino acids. II. Experimental and computational evidence using biomembrane models. Int J Pharm 310:53–63.
   PubMed Web of Science ®Google Scholar
• D. Quartermain, J. Mower, M. F. Rafferty, R. L. Herting, and T. H. Lanthorn. (1994). Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 257:7–12.
   PubMed Web of Science ®Google Scholar
• L. T. Thompson, J. R. Moskal, and J. F. Disterhoft. (1992). Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine. Nature 359:638–41.
   PubMed Web of Science ®Google Scholar
• B. N. Van Berckel, C. N. Evenblij, B. J. van Loon, M. F. Maas, M. A. van der Geld, H. J. Wynne, J. M. van Ree, and R. S. Kahn. (1999). D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: A double-blind, parallel, placebo-controlled study. Neuropsychopharmacol 21:203–10.
   PubMed Web of Science ®Google Scholar
• B. N. Van Berckel, R. Hijman, J. A. van der Linden, H. G. Westenberg, J. M. van Ree, and R. S. Kahn. (1996). Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 40:1298–1300.
   PubMed Web of Science ®Google Scholar
• S. P. Vyas, S. Goswami, and Ranjit Sing. (1995). Liposome-based nasal delivery system of nifrdipine: development and characterization. Int. J. Pharm. 118 (1):20–30.
   Google Scholar
• G. B. Watson, M. A. Bolanowski, and M. P. Baganoff. (1990). D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 510:158–60.
   PubMed Web of Science ®Google Scholar
• M. C. Woodle, L. R. Collins, E. Sponsler, N. Kossovsky, D. Papahadjopoulos, and F. J. Martin. (1992). Sterically stabilized liposomes. Reduction in electrophoretic mobility but not electrostatic surface potential. Biophys J 61:902–10.
   PubMed Web of Science ®Google Scholar
• A M. Zhivkov. (2007). Dependence of depletion layer thickness on polymer concentration determined by Vincent's pragmatic and Donath's electrophoretic theories. J Colloid Interface Sci 313:122–27.
   Google Scholar